NVAC Influenza Working Group Vaccine Research, Development and Production.

Slides:

Advertisements

Similar presentations

KANSAS STATE GENETICS PLAN - AN OVERVIEW Presented by Linda Williams MT(ASCP) Newborn Screening Follow-up Coordinator Kansas Department of Health and Environment.

Advertisements

The NVPO Unmet Needs Program: FY 2006 Update Ben Schwartz National Vaccine Program Office National Vaccine Advisory Committee Meeting, June 2006.

Wrap-up of Day 1. Plenary One: Regional and Global Update Update of global situation and response to pandemic (H1N1) Dr Wenqing Zhang Regional.

1 Proposed Pharmacovigilance Plan for H5N1 Influenza Virus Vaccine Patrick Caubel, MD, PhD Head of Pharmacovigilance North America February 27, 2007.

Pandemic Influenza Catherine Donovan, MD. MHSc. CIPHI, Newfoundland and Labrador, Oct 25, 2005 Eastern Region

1. 2 The Public Health Agency of Canada Pandemic Influenza Preparedness: An Overview Dr. Paul Gully Deputy Chief Public Health Officer Ottawa, 19 January.

Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.

Health System Response to Pandemic Influenza: A Clinician's Perspective Mary M. Klote, MD Walter Reed Army Medical Center.

Melissa House, Ph.D.: Public Health Walden University PUBH Instructor: Dr. Robert Marino Spring Qtr, 2011 D ISASTER P REPAREDNESS P ANDEMIC I NFLUENZA.

Pandemic Influenza Preparedness Kentucky Department for Public Health Department for Public Health.

Maintaining Essential Business and Community Services During a Pandemic Paul R. Patrick, Director Bureau of Emergency Medical Services Utah Department.

The Healthy Mothers, Healthy Babies Plan: An assessment of South Carolina’s efforts to reduce infant mortality and improve maternal and child health outcomes.

Roll Back Malaria Monitoring & Evaluation Reference Group (MERG) RBM 12 th Partnership Board Meeting Geneva, May 10-11, 2007 Bernard Nahlen Bernard Nahlen.

Biotechnology VC Funding, Vaccines, Technology. What is Biotechnology? Biotech: refers to the use of living organisms or their products to modify human.

Community System Strengthening and Dual Track Financing Mauro Guarinieri Civil Society Officer, Asia Unit Cancun, 2-December-2009.

Public Health Sector Strategic Plan Update to alPHa board April, 2013.

Influenza Vaccine Development

Raymond A. Strikas, MD Associate Director for Adult Immunization Immunization Services Division National Immunization Program Coordinating Center for Infectious.

Prevention and Control of Viral Hepatitis Infection: WHO Framework for Global Action Prevention and Control of Viral Hepatitis Infection: WHO Framework.

Multifaceted HPV Vaccination Strategies in California Achieving the Promise Avoiding the Pitfalls Heidi M. Bauer, MD MS MPH California Department of Public.

Pandemic Influenza; A Harbinger of Things to Come Michael T Osterholm PhD, MPH Director, Center for Infectious Disease Research and Policy Associate Director,

Learning from the 2009 H1N1 Pandemic Response 1 Daniel S. Miller MD, MPH Director, International Influenza Unit Office of the Secretary Office of Global.

Surveillance Activities during Pandemic Phases Anne-Luise Winter APHEO-COMOH Workshop Toronto February 1, 2007.

January 27, th BVDV Symposium –BVDV Variability: Impact on Virulence, Host Range, and Control Bovine Viral Diarrhea Virus (BVDV) Research Needs.

THE NATIONAL INFLUENZA VACCINE SUMMIT: UPDATE Raymond A. Strikas, M.D. Immunization Services Division National Immunization Program Coordinating Center.

Canterbury Flu Group Shorter ED Stays Winter Planning April 2013.

Sharing Data: Improving Outcomes Stuart MacDonald 

Recommendations and a Plan for Preventing Preterm Birth Secretary’s Advisory Committee on Infant Mortality (SACIM) August 10, 2015.

The Global Fund-Private Sector Survey Feedback on preliminary findings GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg,

World Health Organization, Regional Office for The Western Pacific Regional Activities Report and Preparation for the Upcoming Influenza Seasons THE 3rd.

IOM Report on Financing Vaccines in the 21 st Century: National Vaccine Advisory Committee Follow-up Alan R. Hinman, MD, MPH Chair, NVAC Workgroup on IOM.

Case study: infectious disease Professor Anne Johnson FMedSci Head, Department of Primary Care and Population Sciences, Royal Free and University College.

Food and Drug Administration

Global Partnership on Disability and Development What is the GPDD? Presentation to JICA Group Training Course HIV/AIDS Section Judith Heumann, Lead Consultant,

U.S. Pandemic Influenza Preparedness and Response: Update & Progress Report “The pandemic influenza clock is ticking. We just don’t know what time it is.”

Assessment of recommendations of the 5 past ACHR sessions 26 th – 30 th Dulitha N. Fernando.

Epilepsy and WHO | 17 Oct |1 | WHO's six-point agenda The overarching health needs 1.Promoting development 2.Fostering health security The strategic.

Meeting the Challenge of Pandemic Vaccine Preparedness: FDA Perspectives Jesse L. Goodman, MD, MPH Director, Center for Biologics Evaluation and Research.

America Responds: An HHS 2009-H1N1 Retrospective to Advance All Hazards Preparedness Discussion with the National Vaccine Advisory Committee June 3, 2010.

The AIDS Vaccine Policy Agenda Holly J. Wong Vice President, Public Policy International AIDS Vaccine Initiative (IAVI) Vienna, Austria International AIDS.

Influenza Vaccination Update for Jeanne M. Santoli, MD, MPH Deputy Director, Immunization Services Division National Center for Immunization and.

National Vaccine Advisory Committee Report from the Chair Gus Birkhead, MD, MPH NVAC Chair February 3, 2010.

XVII INTERNATIONAL AIDS CONFERENCE PANCAP Satellite Meeting Hon Douglas Slater, Minister of Health, St. Vincent and the Grenadines.

DRAFT PIP Framework Partnership Contribution: Factors to consider in selecting countries DRAFT PIP Framework Partnership Contribution: Factors to consider.

(Slide 1 of 22) Response to the National Vaccine Advisory Committee Recommendations on the Immunization Safety Office Scientific Agenda Frank DeStefano,

Conclusions 3 rd Meeting of National Influenza Centres in the Western Pacific and South East Asia Regions 18 – 20 August 2009 Beijing, China.

Strategies to Consider to Improve ACCV Effectiveness Presentation to ACCV Vito Caserta M.D., M.P.H. Vincent Matanoski, J.D. December 5,

Pandemic Vaccines Current and Future Issues 30 January 2007 Beijing Keiji Fukuda Global Influenza Programme.

Consultant Advance Research Team. Outline UNDERSTANDING M&E DATA NEEDS PEOPLE, PARTNERSHIP AND PLANNING 1.Organizational structures with HIV M&E functions.

John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group Two: Controlling Animal Influenza.

Interactions between health systems and Global Health Initiatives – what we learnt to inform research methodology Joseph Perriëns on behalf of Badara Samb.

Dr. Gopakumar K Thampi, Public Affairs Foundation, Bangalore CITIZEN REPORT CARDS & REFORMS Exploring the Scope.

Situation Analysis. 2 Policy and planning Key messages Situation analysis is more than burden of disease (BoD) Also include SDH, population expectations.

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

Joint Meeting of the Coverage and Future Vaccines Subcommittees October 5, 2004.

1 NVAC Washington, D.C. February 3, Agenda I.Overview of Influenza Vaccine Production and Development II.Vaccine Supply/Demand: Recent Trends.

Pandemic Influenza: Planning and Preparedness Ben Schwartz, M.D. National Vaccine Program Office, U.S. Department of Health and Human Services NVAC Meeting,

Advisory Forum, July 2005 Outcome of the first retreat of ECDC Management Team (EXC) 4-5 July 2005 Krägga Herrgård Zsuzsanna Jakab Director ECDC.

Adult Immunization: Goals, Challenges, and a role for the National Vaccine Advisory Committee October 22, 2007 Raymond A. Strikas, MD National Vaccine.

Rome Donors Meeting September 7th1 Consultation of AMC concept with key stakeholders Rome Donors Meeting September 7 th, 2006.

The National Vaccine Plan Update: Recent Activities and Next Steps Raymond A. Strikas, MD National Vaccine Program Office Department of Health and Human.

1. Connecting Health Plans and Public Health to Improve Vaccine Delivery CDC Billing Project Billing Planning All-Projects’ Conference Call June 26, 2012;

NVAC Influenza Working Group: Preliminary Report Charles Helms, M.D., Ph.D. June 1, 2004.

Lesson 14Page 1 of 26 Surveillance Issues in Developing Countries Lesson 14.

The NVPO Unmet Needs Program: Looking Back and Moving Forward Ben Schwartz National Vaccine Program Office National Vaccine Advisory Committee Meeting,

Making South Africa a Global Leader in Harnessing ICTs for Socio-economic Development Overview of Local and Digital Content Strategy of South Africa: Creation,

The Ontario Experience National Immunization Conference

Finance & Planning Committee of the San Francisco Health Commission

Key Area 3.7: Immunisation

Updating the National Vaccine Plan: A roadmap for the next decade A National, not Federal, Plan December 11, 2009.

Presentation transcript:

NVAC Influenza Working Group Vaccine Research, Development and Production

Vaccine Research Subgroup Ann Arvin (chair) Bruce Gellin (NVPO staff)

Vaccine Research Subgroup Activities Conference calls Initial survey of agencies efforts in research Stakeholder interviews (vaccine companies) National Influenza Vaccine Summit

Vaccine Research Subgroup – Issues Vaccine has limited efficacy in populations most vulnerable to influenza and its complications; a more effective vaccine is needed Better understanding of burden of disease may be needed to adequately measure impacts of various interventions (e.g., vaccine effectiveness, evolving nature of virus) Vaccine production: growing use of vaccine in US and globally, but current methods are cumbersome and relies on 50+ year old methods

Vaccine Research Subgroup Preliminary Assessment Issues for further discussion (1) Intersection of annual (“interpandemic”) influenza and pandemic preparedness Focused research to understanding of limitations of existing vaccines in vulnerable populations –Are different vaccines needed for different populations? Influenza immunity and immune evasion Potential role of adjuvants in enhancing immune response to influenza vaccines Dynamics of herd immunity: Implications for immunizations strategies (e.g., universal immunization) Delivery technologies: Facilitating vaccination uptake (e.g., needle-less technologies)

Vaccine Research Subgroup Preliminary Assessment Issues for further discussion (2) New technology for vaccine production (reverse genetics, engineered cell lines, mechanics of production process) Better approaches to understanding and predicting influenza virulence and transmission dynamics Veterinary/Human interface Research infrastructure/resource needs (BSL 3 labs, reagents) Public/Private Partnerships: Input from stakeholder in the development of a national research strategy Global harmonization: Influenza vaccine as model for vaccine harmonization efforts (FDA, EMEA, others)

Next Generation Influenza Vaccine “Public funding should give priority to research on cross-subtype vaccines conferring long-lasting protection….If the vaccine confers long-lasting immunity, preventive vaccination for a future pandemic will be possible…” WHO Consultation on Priority Public Health Interventions Before and During an Influenza Pandemic – March

Vaccine Research Subgroup Preliminary Assessment Initial Conclusions: HHS should consider conducting a comprehensive cross-agency overview of all ongoing and planned research with the goal of developing a coherent national influenza research agenda –Broad range of overlapping research needs Innovation for developing improved needs to be encouraged and enhanced –Enhance effectiveness –Broad protection –Production technologies